Glypican-3 Peptide Vaccines: Training Your Immune System to Target Cancer
Peptide vaccines targeting glypican-3 successfully triggered cancer-killing immune responses in most patients across five clinical trials, offering a complement to checkpoint immunotherapy.
Quick Facts
What This Study Found
Glypican-3 peptide vaccines successfully induced cancer-specific cytotoxic T lymphocytes (CTLs) in most patients across multiple clinical trials (five registered trials). The peptide showed extreme cancer specificity when restricted to HLA-A24 and HLA-A2 molecules. The review also found that neoantigen-based personalized immunotherapy shows potential for eliciting cancer regression, and both approaches may complement immune checkpoint inhibitors for patients who don't respond to checkpoint therapy alone.
Key Numbers
How They Did This
The authors summarized results from five clinical trials (registered in the UMIN Clinical Trials Registry) testing glypican-3 peptide vaccines in cancer patients. They also reviewed the current state of neoantigen-based personalized cancer immunotherapy, drawing on their own research program and published literature.
Why This Research Matters
Immune checkpoint inhibitors have transformed cancer treatment, but many patients don't respond. Peptide vaccines targeting glypican-3 or tumor-specific neoantigens offer complementary strategies that could fill this gap — especially for cancers like hepatocellular carcinoma where glypican-3 is highly expressed.
The Bigger Picture
Cancer immunotherapy is moving toward combination strategies. Peptide vaccines like these could be paired with checkpoint inhibitors to boost response rates — the vaccine teaches the immune system what to attack, while the checkpoint inhibitor removes the brakes. The emerging neoantigen approach takes this even further by creating vaccines customized to each patient's specific tumor mutations.
What This Study Doesn't Tell Us
The abstract does not provide specific response rates, survival data, or detailed outcomes from the clinical trials mentioned. As a review summarizing the authors' own work, it may present a favorable view of the results. The specific cancer types and patient populations across the five trials are not detailed in the abstract.
Questions This Raises
- ?How effective are glypican-3 peptide vaccines when combined with immune checkpoint inhibitors?
- ?Can neoantigen-based vaccines be manufactured quickly and cheaply enough for widespread clinical use?
- ?Which cancer types beyond hepatocellular carcinoma express enough glypican-3 to be targeted by these vaccines?
Trust & Context
- Key Stat:
- Most patients responded Glypican-3 peptide vaccines induced specific cancer-killing T cells in the majority of patients across five clinical trials
- Evidence Grade:
- Based on five registered clinical trials and the authors' direct research experience, this represents moderate clinical evidence. However, the abstract lacks specific outcome data (response rates, survival), and the review nature means results are summarized rather than independently analyzed.
- Study Age:
- Published in 2018, this review captures an active period of peptide vaccine clinical development. The neoantigen field has advanced significantly since, with several personalized cancer vaccines entering later-stage trials.
- Original Title:
- Cancer immunotherapy-targeted glypican-3 or neoantigens.
- Published In:
- Cancer science, 109(3), 531-541 (2018)
- Authors:
- Shimizu, Yasuhiro, Suzuki, Toshihiro(4), Yoshikawa, Toshiaki, Tsuchiya, Nobuhiro, Sawada, Yu, Endo, Itaru, Nakatsura, Tetsuya
- Database ID:
- RPEP-03902
Evidence Hierarchy
Frequently Asked Questions
What is glypican-3 and why is it a good cancer vaccine target?
Glypican-3 is a protein found on the surface of certain cancer cells — particularly liver cancer — but rarely on normal cells. This 'extreme cancer specificity' makes it an ideal target: a vaccine that trains the immune system to attack glypican-3-expressing cells would destroy tumors while leaving healthy tissue alone.
How do peptide cancer vaccines differ from checkpoint inhibitors?
Checkpoint inhibitors remove the brakes on the immune system but don't tell it what to attack. Peptide vaccines do the opposite: they teach the immune system to recognize specific cancer proteins. Combining both approaches — targeting and releasing the brakes — could be more effective than either alone.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-03902APA
Shimizu, Yasuhiro; Suzuki, Toshihiro; Yoshikawa, Toshiaki; Tsuchiya, Nobuhiro; Sawada, Yu; Endo, Itaru; Nakatsura, Tetsuya. (2018). Cancer immunotherapy-targeted glypican-3 or neoantigens.. Cancer science, 109(3), 531-541. https://doi.org/10.1111/cas.13485
MLA
Shimizu, Yasuhiro, et al. "Cancer immunotherapy-targeted glypican-3 or neoantigens.." Cancer science, 2018. https://doi.org/10.1111/cas.13485
RethinkPeptides
RethinkPeptides Research Database. "Cancer immunotherapy-targeted glypican-3 or neoantigens." RPEP-03902. Retrieved from https://rethinkpeptides.com/research/shimizu-2018-cancer-immunotherapytargeted-glypican3-or
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.